IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer

Hilary Bilyard; Charlotte Mines; Laura Rosa Brunet; Angus Dalgleish; Frances Macintosh

doi:10.1186/2051-1426-2-S3-P83

Article info

PDF

Poster Presentation

IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer

Free

Authors

Hilary Bilyard Immodulon Therapeutics Ltd London United Kingdom PubMed articles Google scholar articles
Charlotte Mines Immodulon Therapeutics Ltd London United Kingdom PubMed articles Google scholar articles
Laura Rosa Brunet Immodulon Therapeutics Ltd London United Kingdom PubMed articles Google scholar articles
Angus Dalgleish St. George's University of London London United Kingdom PubMed articles Google scholar articles
Frances Macintosh Immodulon Therapeutics Ltd London United Kingdom PubMed articles Google scholar articles

Citation

Bilyard H, Mines C, Brunet LR, et al

IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer

Journal for ImmunoTherapy of Cancer 2014;2:P83. doi: 10.1186/2051-1426-2-S3-P83

Online issue publication

March 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password